Teva’s shares have underperformed competitors’ this year amid speculation the multiple sclerosis medicine Copaxone may lose market share to new treatments such as Novartis AG’s Gilenya. Photographer: Akos Stiller/Bloomberg
Teva’s shares have underperformed competitors’ this year amid speculation the multiple sclerosis medicine Copaxone may lose market share to new treatments such as Novartis AG’s Gilenya. Photographer: Akos Stiller/Bloomberg
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=802693674&utmp=%2Fphoto%2F2012-11-30%2Fteva-sees-2013-sales-profit-below-analyst-estimates.html&utmhn=10.248.179.17&utmac=UA-11413116-12&utmhid=953754622)